Zenodo (CERN European Organization for Nuclear Research)
October 24, 2026
Odin Loch
preprint
Background. Safety is a property of a drug, in a population, in a context. Pharmaceutical MDMA (midomafetamine) given in a monitored psychotherapy trial, and material sold as ecstasy or MDMA outside that setting, are different exposures. This preprint compares those contexts side by side. It does not produce one pooled safety number. Methods. This is a rapid computational evidence synthesis:...
Brazilian Journal of Health Review
October 23, 2026
Ana Beatriz Manfrinato Batistella, Anny Izumi Toma, Bruna Corrêa Santini et al.
O transtorno depressivo maior (TDM) permanece como importante desafio terapêutico devido à resistência ao tratamento apresentada por parte dos pacientes, despertando interesse em alternativas como a psilocibina. Trata-se de uma substância psicodélica presente em espécies de cogumelos, cuja principal ação ocorre por agonismo dos receptores serotoninérgicos 5-HT2A e 5-HT1A, promovendo alterações...
Zenodo (CERN European Organization for Nuclear Research)
October 21, 2026
Peter McGrath
preprint
Title: DMT, Salvinorin A, and Stress Regulation: An Exploratory Neuropharmacological Research Proposal Creator: Peter McGrath Affiliation: Appalachian State University Resource type: Publication — Working Paper Description: This independent undergraduate research proposal examines differences between the serotonergic mechanisms of N,N-DMT and the kappa-opioid receptor activity of salvinorin A,...
Psychedelic Medicine
October 21, 2026
Michael D. Masucci, Alex S. Cohen, Christopher R. Cox et al.
Background: Within the last decade, ayahuasca, a brew containing a serotonin 2A receptor agonist (i.e., a classical psychedelic compound), has received increased attention as a possible intervention for posttraumatic stress disorder. Ayahuasca has demonstrated potential for long-term symptom reduction, but the biobehavioral changes caused by ayahuasca have not been defined quantitatively or...
Zenodo (CERN European Organization for Nuclear Research)
October 20, 2026
Lara Vervloet Carvalho, Sarah Isabela Magalhães Costa, Nathália Marques Santos et al.
preprint
As terapias assistidas por psicodélicos emergiram, na última década, como estratégia de investigação de destaque para transtornos psiquiátricos refratários às abordagens convencionais. Em ensaio de fase 2 controlado, dose única de 25 mg de psilocibina produziu redução média de 12,0 pontos na escala MADRS em pacientes com depressão resistente ao tratamento, superior à condição controle de 1 mg....
Pharmaceuticals
October 19, 2026
Daniel Szawarnoga, Joanna Fojcik, Michał Kamil Górski et al.
Treatment-resistant depression (TRD) remains one of the most clinically challenging forms of depressive disorders. In many patients, reduction in symptom severity does not translate into full functional recovery; therefore, assessment of treatment effectiveness should also include health-related quality of life (HRQoL). Objective: The aim of the study was to compare changes in HRQoL in patients...
Journal of Neurotrauma
October 19, 2026
Hoda K AbouEich, Ali Izadi, Jonathan Lifshitz et al.
There are currently no available effective pharmacological therapies for treating chronic cognitive deficits after traumatic brain injury (TBI). Psychoplastogens, including atypical psychedelics, classical serotonergic psychedelics, and neuroplastogens, are a class of small molecule drugs that can enhance neuroplasticity by inducing rapid and sustained effects on neuronal architecture and...
Therapeutics
October 19, 2026
Lukasz Szarpak, Michal Pruc, Dorota Jablonska-Moczulo et al.
Background/Objectives: Treatment-resistant depression (TRD) is heterogeneous and recurrent. Psilocybin administered with structured psychological support can reduce symptoms rapidly. Support protocols differ in content and intensity, and trial design complicates estimates of the specific drug effect and durability. We reviewed efficacy, durability, mechanisms, safety, and clinical delivery in...
Psychopharmacology
October 19, 2026
Landon M. Klein, Jared M. Kopelman, Richard F Sharp et al.
Classical psychedelic drugs such as the tryptamine psilocybin can alter temporal perception. Previously, the phenylethylamine psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI), a 5-HT2A receptor agonist, altered timing precision and accuracy in mice performing the discrete-trials temporal discrimination task (TDT), a retrospective timing task where subjects differentially respond depending on...
Trials
October 14, 2026
Luca Pani, Fabio Tascedda
Abstract: Background: The registry record of psychedelic and related rapid-acting compounds is large, heterogeneous and laborious to synthesize by hand. We tested whether a large language model (LLM) with live access to the ClinicalTrials.gov application programming interface (API) could produce a timely, structured and reproducible characterization of this landscape. Methods: Cross-sectional...